Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles
Grapefruit Benefits

The PATH Malaria Vaccine Initiative And Crucell Announce Collaboration To Test New Adenovirus-based Malaria Vaccine Approach
The US-based PATH Malaria Vaccine Initiative (MVI), the United States Agency for International Development (USAID) Malaria Vaccine Development Program (MVDP), and Dutch biopharmaceutical company Crucell N.V. (Euronext, Nasdaq: CRXL; Swiss Exchange: CRX) today announced a collaboration to accelerate development of a promising type of malaria vaccine. Through funding from the USAID MVDP, the partners will conduct studies to determine the effectiveness of Crucell"s novel prime-boost vaccine approach against the malaria parasite, Plasmodium falciparum. This approach uses Crucell"s proprietary recombinant adenoviruses (a type of virus associated with the common cold and other mild respiratory infections) to deliver a malaria antigen to the immune system.
generic viagra online
Body Chemistry May Identify Type 2 Risk, UK
Body chemistry changes that lead to Type 2 diabetes begin several years before symptoms become apparent, according to new research.
News of the day
Lower College GPA And Evening Chronotype In High School Students Linked
According to a research abstract at SLEEP 2009, the 23rd Annual Meeting of the Associated Professional Sleep Societies, students who consider themselves to be evening types (that is someone who feels more alert and does their best work later in the day) have poorer sleep hygiene scores than morning and intermediate types. Sleep hygiene is the group of behaviors linked to good sleep and alertness. Examples include having a regular bedtime routine, a regular wake time, a regular bed time, and sleeping in a comfortable bed. The researchers found that this poor sleep hygiene was related to poorer academic performance and a decline in grade point average (GPA) during the transition from high school to college.
Medical Devices

Respironics Issues North American Recall Of SmartMonitor(R)2 Infant Apnea Monitor

Respironics announced today that it has voluntarily recalled 4,992 infant apnea monitors. This recall of the SmartMonitor®2 models 4002 and 4003 is being conducted due to the possibility of an audible alarm failure. Caregivers or parents who are using a SmartMonitor 2 Infant Apnea Monitor for their infant, should contact their homecare provider immediately to determine if their device is affected. However, they should continue using the apnea monitor until it is replaced, unless directed otherwise by a physician. The SmartMonitor 2 Infant Apnea Monitor is intended for use in the continuous monitoring of respiration and heart rate of infant patients in a home or hospital environment. The monitor detects and alarms for periods of central apnea and high or low heart rates. If the device fails to alarm during an apnea or heart rate event, the device will not deliver an audible alert to direct the caregiver to respond to the patient. There is a possibility that the lack of response by a caregiver to an apnea or heart rate event may result in serious injury or death. Even if the audible alarm fails, the unit will still trigger a visual alert (red lights will come on). The infant apnea monitors affected by this recall have been distributed in the United States and Canada. Respironics provided notification of the recall to distributors and user providers, sales personnel and customers by letter and phone beginning on April 27, 2009. The firm is continuing to contact customers to arrange for the return of all the recalled apnea monitors. Respironics has received one report of an alarm failure; however no injury resulted. Respironics has notified the U.S. Food & Drug Administration (FDA) of its decision to voluntarily recall the affected product. Homecare providers with questions may contact Respironics Customer Service at 1-877-387-3311. Any adverse reactions experienced with the use of this product should be reported to the FDA"s MedWatch Program by phone at 1-800-FDA-1088, by fax at 1-800-FDA-0178, by mail at MedWatch, HF-2, FDA, 5600 Fishers Lane, Rockville, MD 20852-9787, or on the MedWatch website at http://www.fda.gov/medwatch. U.S. Food & Drug Administration


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009